Kanghong Pharmaceuticals' first-half profit was 310 million yuan, up 33% YoY

On the evening of August 28, Kanghong Pharmaceuticals disclosed its 2018 half-yearly report. From January to June, the Company achieved operating income of RMB1.383 billion, up 1.03% YoY, while net income attributable to shareholders of listed companies was RMB310 million, up 33.13% YoY, and basic earnings per share was RMB0.46.
half of this year, the company to technological innovation as the main line, in the ophthalmology, central nervous system, digestive system and other fields continue to innovate and enrich the series of patented varieties with Kanghong characteristics structure. In the field of ophthalmology, compassip eye injection (commodity name: Lang Mu) U.S. Phase III clinical initiation in May 2018.
's independent research and development of Class I bio-innovative drugs with independent intellectual property rights, used to treat trauma, chemical burns, corneal transplantation induced by the new blood vessels KH906 eye drops have been issued by the State Food and Drug Administration "clinical approval of drugs."
In the field of the central nervous system, the company applied for the treatment of Alzheimer's disease of hydrochloric acid dornatin tablets, hydrochloric acid donnellan tablets, for the treatment of severe depression in adults, vossetine tablets have been issued by the State Food and Drug Administration "drug clinical trial approval", another new drug for the treatment of Alzheimer's disease KH110 is also in the research and development stage.
In the field of digestive system, the treatment of a variety of physical tumors accompanied by pathological vascular growth, such as bowel cancer, lung cancer and with international invention patents of a class 1 biological new drug "recombinant human vascular endotent growth factor subject - antibody fusion protein injection (intravenous administration)" in May obtained the drug clinical trial approval, the company applied for the Eso meprazole magnesium intestinal capsule has been issued by the State Food and Drug Administration "drug clinical trial approval."
other areas, products in the research and development stage include KH901, a class 1 bio-new drug with international patents for therapeutic tumor vaccines.
half-yearly report, the company also made a forecast for the first three quarters of the results. The company expects to achieve net profit attributable to shareholders of listed companies in january-September of RMB43.645 million to RMB56.115 million, up 5% to 35% YoY. For the reasons for the change in performance, the company said that with the professional academic promotion and dissemination of continuous deepening, the company's operating performance continued to grow. (China Securities News)